AMIGO1 and pancreatic adenocarcinoma: Collectively, these findings demonstrate that AMIGO2 serves as a robust prognostic indicator in PAAD, with its elevated expression specifically associated with unfavorable clinical outcomes compared with other AMIGO family members or cancer types.